independent verification regarding accuracy of pathologic diagnosis; and delayed reporting or underreporting to the Surveillance, Epidemiology and End Results registries. Despite these limitations, the major strengths of the study were use of a large nationally representative quality-controlled population-based database, multivariable analysis controlling for a range of confounders, and use of cause-specific survival as an end point.
Retrospective effects of the American Joint Committee on Cancer's eighth edition guidelines for staging melanoma To the Editor: The American Joint Committee on Cancer (AJCC) published the eighth edition of its cancer staging manual in October 2016. 1 In the new evidence-based guidelines, the criteria for classification of stage pT1 melanomas have been modified. The presence of mitoses is no longer a criterion, although it is still recommended that the rate be reported. Lesions are now substaged into pT1a and pT1b categories on the basis of presence or absence of ulceration (as in the previous edition), as well as on the basis of a Breslow depth more or less than 0.8 mm.
2 Nonulcerated melanomas thinner than 0.8 mm are classified as pT1a, and melanomas thicker than 0.8 mm and/or with ulceration are classified as pT1b. Depth may be reported to a hundredth of a millimeter but should be rounded to the nearest tenth of a millimeter for classification. We sought to apply the new guidelines to previous stage 1 melanomas to determine the extent to which their classification would change. All dermatopathology reports spanning September 2011 through April 2017 from the University of Texas Medical Branch were retrospectively reviewed for the diagnosis of melanoma. Cases were included if they were invasive melanoma with a Breslow depth less than 1.0 mm and were classified as stage pT1a or pT1b. Cases were not included if the deep margin was involved in the specimen and the definitive Breslow depth and primary tumor stage could not be determined. A total of 102 cases of stage pT1 melanoma were included; 83.3% of them were classified as pT1a and 16.7% were classified as pT1b according to the AJCC seventh edition staging guidelines. We subsequently reclassified all 102 stage pT1 melanomas using the new AJCC eighth edition staging guidelines. We found that 17 cases changed classification from T1a to T1b (16.7% of all diagnosed pT1 melanomas), whereas 8 cases changed classification from T1b to T1a (7.8% of all diagnosed pT1 melanomas). A total of 77 cases (75.5% of the pT1 melanomas) remained unchanged in the new classification system (Table I) . These changes resulted in a decrease of 8.8% in stage pT1a melanomas and an increase of 8.8% in stage pT1b melanomas (Table II) .
Although this study is limited by its retrospective nature and relatively small number of cases, our data suggest that implementation of the eighth edition of the AJCC guidelines will result in an increase in the proportion of pT1b melanomas and a decrease in the proportion of pT1a melanomas. January 1, 2018, is the current implementation date for the AJCC eighth edition. 3 An increase in pT1b melanoma would conceivably translate to an increase in clinical stage IB melanomas and a possible increase in the number of sentinel lymph node biopsies performed on thin melanomas on the basis of the National Comprehensive Cancer Network clinical practice guidelines for melanoma. 4 However, sentinel lymph node biopsy in thin melanomas remains a topic of controversy. Future, prospective studies are needed to determine whether the changes in the substaging of pT1 melanomas with implementation of the AJCC eighth edition translate to survival benefit or affect melanoma-related morbidity. 
